Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Indivior Pharmaceuticals (INDV) Income towards Parent Company (2024 - 2025)

Indivior Pharmaceuticals (INDV) has 2 years of Income towards Parent Company data on record, last reported at $802.0 million in Q4 2025.

  • For Q4 2025, Income towards Parent Company rose 3719.05% year-over-year to $802.0 million; the TTM value through Dec 2025 reached $965.0 million, up 13685.71%, while the annual FY2025 figure was $210.0 million, 2233.33% up from the prior year.
  • Income towards Parent Company reached $802.0 million in Q4 2025 per INDV's latest filing, up from $42.0 million in the prior quarter.
  • Across five years, Income towards Parent Company topped out at $802.0 million in Q4 2025 and bottomed at -$98.0 million in Q2 2024.